CO5271736A1 - Forma triturada - Google Patents

Forma triturada

Info

Publication number
CO5271736A1
CO5271736A1 CO00091759A CO00091759A CO5271736A1 CO 5271736 A1 CO5271736 A1 CO 5271736A1 CO 00091759 A CO00091759 A CO 00091759A CO 00091759 A CO00091759 A CO 00091759A CO 5271736 A1 CO5271736 A1 CO 5271736A1
Authority
CO
Colombia
Prior art keywords
ethoxy
shredded form
methanesulfonyloxyphenyl
mfi
jpeg
Prior art date
Application number
CO00091759A
Other languages
English (en)
Inventor
Hallgren Agneta
Roos Kristina
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5271736A1 publication Critical patent/CO5271736A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una forma de partícula de tamaño reducido de ya sea de ácido (S)-2- etoxi -3- [4-(2-{4-metanosulfoniloxifenil}etoxi)fenil] propiónico como se muestra en la fórmula I abajo<EMI FILE="00091759_1" ID="1" IMF=JPEG >o sales farmacéuticamente aceptables del mismo o un solvato o cualquiera de los dos.
CO00091759A 1999-12-03 2000-11-30 Forma triturada CO5271736A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904413A SE9904413D0 (sv) 1999-12-03 1999-12-03 Comminuted form

Publications (1)

Publication Number Publication Date
CO5271736A1 true CO5271736A1 (es) 2003-04-30

Family

ID=20417978

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00091759A CO5271736A1 (es) 1999-12-03 2000-11-30 Forma triturada

Country Status (32)

Country Link
EP (1) EP1237854B1 (es)
JP (1) JP2003515580A (es)
KR (1) KR20020067538A (es)
CN (1) CN1216859C (es)
AR (1) AR029456A1 (es)
AT (1) ATE251131T1 (es)
AU (1) AU766036B2 (es)
BR (1) BR0016135A (es)
CA (1) CA2392029A1 (es)
CO (1) CO5271736A1 (es)
CZ (1) CZ20021839A3 (es)
DE (1) DE60005710T2 (es)
DK (1) DK1237854T3 (es)
EE (1) EE200200284A (es)
ES (1) ES2208444T3 (es)
HK (1) HK1049324B (es)
HU (1) HUP0203692A3 (es)
IL (1) IL149516A0 (es)
IS (1) IS6399A (es)
MX (1) MXPA02005165A (es)
MY (1) MY125099A (es)
NO (1) NO20022591L (es)
NZ (1) NZ518926A (es)
PL (1) PL355372A1 (es)
PT (1) PT1237854E (es)
RU (1) RU2248966C2 (es)
SE (1) SE9904413D0 (es)
SK (1) SK7662002A3 (es)
TR (1) TR200400003T4 (es)
UA (1) UA73959C2 (es)
WO (1) WO2001040169A1 (es)
ZA (1) ZA200203797B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999016758A1 (en) 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
GB2364304B (en) 1997-10-27 2003-04-23 Reddy Research Foundation Novel tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
CA2307068C (en) 1997-10-27 2007-04-10 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
AU763087B2 (en) 1998-10-29 2003-07-10 Dr. Reddy's Laboratories Limited An improved process for the preparation of new antidiabetic agents
US6531596B1 (en) 1998-10-29 2003-03-11 Dr. Reddy's Laboratories Ltd. Process for the preparation of new antidiabetic agents
US6897199B2 (en) 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
US20100179131A1 (en) 2006-09-07 2010-07-15 Nycomed Gmbh Combination treatment for diabetes mellitus
WO2008108735A1 (en) 2007-03-08 2008-09-12 Albireo Ab 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
EP2152663B1 (en) 2007-06-04 2014-03-19 Ben Gurion University of the Negev Research and Development Authority Tri-aryl compounds and compositions comprising the same
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
WO2015068156A1 (en) 2013-11-05 2015-05-14 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704873D0 (sv) * 1997-12-23 1997-12-23 Astra Ab Sampling apparatus
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues

Also Published As

Publication number Publication date
CZ20021839A3 (cs) 2002-08-14
CN1402704A (zh) 2003-03-12
ATE251131T1 (de) 2003-10-15
EP1237854B1 (en) 2003-10-01
UA73959C2 (en) 2005-10-17
BR0016135A (pt) 2002-08-20
ES2208444T3 (es) 2004-06-16
AR029456A1 (es) 2003-07-02
WO2001040169A1 (en) 2001-06-07
NZ518926A (en) 2003-11-28
TR200400003T4 (tr) 2004-02-23
EP1237854A1 (en) 2002-09-11
NO20022591D0 (no) 2002-05-31
NO20022591L (no) 2002-05-31
HUP0203692A2 (hu) 2003-03-28
IS6399A (is) 2002-05-28
HK1049324B (zh) 2004-04-30
CN1216859C (zh) 2005-08-31
IL149516A0 (en) 2002-11-10
AU766036B2 (en) 2003-10-09
HK1049324A1 (en) 2003-05-09
KR20020067538A (ko) 2002-08-22
EE200200284A (et) 2003-08-15
ZA200203797B (en) 2003-08-13
DE60005710D1 (en) 2003-11-06
CA2392029A1 (en) 2001-06-07
DE60005710T2 (de) 2004-08-05
SE9904413D0 (sv) 1999-12-03
AU2034801A (en) 2001-06-12
DK1237854T3 (da) 2004-01-12
PT1237854E (pt) 2004-02-27
RU2002113169A (ru) 2004-01-20
PL355372A1 (en) 2004-04-19
SK7662002A3 (en) 2002-10-08
JP2003515580A (ja) 2003-05-07
MY125099A (en) 2006-07-31
RU2248966C2 (ru) 2005-03-27
MXPA02005165A (es) 2003-09-25
HUP0203692A3 (en) 2005-05-30

Similar Documents

Publication Publication Date Title
CO5271736A1 (es) Forma triturada
CO5271735A1 (es) Forma cristalina
CO5261585A1 (es) Nueva forma cristalina del acido n-[4-[2-(2-amino-4,7- dihidro-4-oxo-3h-pirrolo[2,3-d]pirimidin-5-il)etil] benzoil]-l-glutamico y procedimiento para su preparacion
CO5150238A1 (es) Polimorfos de telmisartan, procedimiento para su preparacion y su empleo para la preparacion de un medicamento
CO5200832A1 (es) Derivados de acidos heterociclicos, o una sal farmaceuticamente aceptable de los mismos, que son agentes antidiabeticos y antiobesidad
CO5261539A1 (es) Compuestos farmaceuticamente activos
CO5160253A1 (es) Complejo de 1,4-benzodiazepinas sustituidas y sulfobutileter -7-ciclodextrina o 2-hidroxipropil-b-ciclodextrina .
CO5280070A1 (es) Compuestos, composiciones farmaceuticas de indazol y metodos para mediar o inhibir la proliferacion celular
EA200600381A1 (ru) Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение в качестве лекарственного средства
CO5140109A1 (es) Compuestos no esteroides antiinflamatorios derivados de 2,3- benzoxazin-1-ona y ftalida y preparados farmaceuticos que los contienen
BR0215411A (pt) Métodos para processar dados e para separar registros previamente conjugados, e, meio legìvel por computador
JP2004510040A5 (es)
CO5190677A1 (es) Formulacion de sal comun y moxifloxacina
CO5251404A1 (es) Compuestos antibioticos de azalida
NO983268D0 (no) Konformasjonsbegrensede aromatiske inhibitorer for mikrosomalt triglyserid-overf°ringsprotein og fremgangsmaae
TR200201668T2 (tr) Vla-4&#39; e bağlı hücre bağlamasının peptidilsiz önleyicileri
CO5271716A1 (es) Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
CO5200839A1 (es) Nuevos compuestos
CO5261552A1 (es) Procedimiento para la obtencion de 1,2,3,4-tetrahidroquino- linas 4-carboxiamino-2-sustituidas
CO5271723A1 (es) Forma triturada
CO5090829A1 (es) Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
EP1216924A3 (en) Bag splitter and wet separator
DE69105135D1 (de) Piperidyl-substituierte indole.
CO5261538A1 (es) Nuevos acidos (aminopropil) metilfosfinicos
SE9902550D0 (sv) New crystalline forms

Legal Events

Date Code Title Description
FC Application refused